PAREXEL Renames Perceptive Informatics Subsidiary
PAREXEL announced a group of initiatives that include a re-designed corporate website
PAREXEL announced a group of initiatives that include a re-designed corporate website, a global marketing and advertising campaign and the rebranding of its technology subsidiary Perceptive Informatics to PAREXEL informatics.
According to the company's press release, the PAREXEL Informatics branding is in response to sponsors seeking multiple solutions from a single service provider. Said Mark A. Goldberg, President and Chief Operating Officer, PAREXEL in that release, "We are more closely integrating our clinical research and technology offerings to meet this need. Toward that end, the new PAREXEL Informatics branding communicates our commitment to providing technology-driven solutions that complement our other clinical trial services, without changing our overall go-to-market strategy."
PAREXEL will maintain the Perceptive brands to identify specific PAREXEL Informatics offerings that have market recognition that has been built over the years. These include Perceptive MyTrials eClinical platform, the Perceptive Partner Program and the Perceptive Institute.
Read the full release here.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Reblozyl Misses Primary Endpoint in Phase III Myelofibrosis Trial but Shows Clinical Promise
July 21st 2025The Phase III INDEPENDENCE trial (NCT04717414) failed to meet its primary endpoint of achieving transfusion independence in patients with myelofibrosis-associated anemia treated with Reblozyl (luspatercept-aamt).
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
